Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Alendronate more effective than alfacalcidol in the prevention of osteoporosis in patients with rheumatic disease who are starting glucocorticoid therapy].

de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen JC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsmat JW.

Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178-85. Dutch.

PMID:
17557758
2.

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.

de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW; STOP Investigators..

N Engl J Med. 2006 Aug 17;355(7):675-84.

3.

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.

Hoes JN, Jacobs JW, Hulsmans HM, De Nijs RN, Lems WF, Bruyn GA, Geusens PP, Bijlsma JW.

Clin Exp Rheumatol. 2010 May-Jun;28(3):354-9. Epub 2010 Jun 23.

PMID:
20406615
4.

Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.

Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.

J Rheumatol. 2007 May;34(5):1051-7. Epub 2007 Apr 1.

PMID:
17407214
5.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

7.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
8.

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.

Takeda S, Kaneoka H, Saito T.

Mod Rheumatol. 2008;18(3):271-6. doi: 10.1007/s10165-008-0055-y. Epub 2008 Apr 22.

PMID:
18427724
9.

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.

Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y.

J Rheumatol. 2008 Nov;35(11):2249-54.

PMID:
19031508
10.

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Yonsei Med J. 2009 Aug 31;50(4):474-81. doi: 10.3349/ymj.2009.50.4.474. Epub 2009 Aug 19.

11.

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.

Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.

12.

Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.

Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.

Arch Dermatol. 2012 Mar;148(3):307-14. doi: 10.1001/archdermatol.2011.354. Epub 2011 Nov 21.

PMID:
22105813
13.

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.

Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M.

Aliment Pharmacol Ther. 2009 Feb 15;29(4):424-30. doi: 10.1111/j.1365-2036.2008.03899.x. Epub 2008 Nov 25.

14.

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A.

Arthritis Rheum. 2001 Jan;44(1):202-11.

15.

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.

Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H, Tohma S, Yamanishi Y, Hasegawa H, Tanimura K, Negoro N, Ueki Y, Kawakami A, Eguchi K, Saito K, Okada Y.

J Bone Miner Metab. 2016 Nov;34(6):646-654. Epub 2015 Aug 26.

PMID:
26308708
16.

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG.

N Engl J Med. 1998 Jul 30;339(5):292-9.

17.

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.

J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1.

PMID:
19487264
18.

A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.

Iwamoto N, Inaba Y, Kobayashi N, Ishida T, Yukizawa Y, Saito T.

J Bone Joint Surg Am. 2011 Jul 6;93(13):1203-9. doi: 10.2106/JBJS.I.01714.

PMID:
21776573
19.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

Supplemental Content

Support Center